Navigation Links
Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
Date:12/2/2008

On Track to File NDA with FDA in Early to Mid-2009

WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its development partner, MonoSol Rx, reported the successful completion of all pivotal bioequivalence studies for a thin film formulation of ondansetron. The ondansetron thin film product is being developed for the prevention of chemotherapy-induced nausea and vomiting, prevention of nausea and vomiting associated with radiotherapy, and post-operative nausea and vomiting.

Subject to final review of the data and discussions with the Food and Drug Administration (FDA), it is anticipated that Strativa and MonoSol Rx could file a New Drug Application (NDA) in early to mid 2009.

In June 2008, MonoSol Rx and Strativa entered into an exclusive licensing agreement under which Strativa acquired the U.S. commercialization rights to the thin film formulation of ondansetron from MonoSol Rx. Under terms of the agreement, MonoSol Rx will receive milestone payments prior to commercial launch and sales-based milestones that could total $23.5 million as well as payments for the purchase of product supply and royalties on net sales. The successful achievement of all pivotal bioequivalence studies triggered a milestone payment to MonoSol Rx.

John A. MacPhee, president of Strativa, said, "Completion of the pivotal bioequivalence trials is a significant milestone in the development and commercialization process for our thin film ondansetron formulation. Working with MonoSol Rx we were able to demonstrate that the thin film formulation is bioequivalent to the FDA approved Zofran ODT(R) product in all human clinical trials."

Anti-emetic therapies constit
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
2. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
3. Introducing Strativa Pharmaceuticals
4. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
5. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
11. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... 2014 Over the last decade, the ... rising R&D budgets and increased acceptance of new filtration ... and biotechnology industries are also catalyzing the growth of ... is expected to grow at a strong CAGR during ... be worth $2,532.6 million by 2019. The market is ...
(Date:9/30/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" ... a Canadian Patent for Inhibition or Reversal of ... claims using thymosin beta 4, various fragments and ... purposes.  The patent will expire in 2021. ... ) RegeneRx is focused on ...
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned subsidiary of ... received tentative approval from the U.S. Food,and Drug ... and 40 mg (base). Nexium(R) (Esomeprazole) is the,second ... annual market sales of,$5.5 billion (IMS -- MAT: ...
... Feb. 7 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ACCP) ... Access, is scheduled to deliver a presentation about the ... on February 13, 2008 at,12:30 pm Eastern Time. The ... City at the Waldorf Astoria Hotel., The presentation ...
... 7 XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ; ... Chief Executive Officer, is scheduled to present at,the ... Bentsur will present an,overview of the Company including ... for the treatment of diabetic neuropathic,pain. Mr. Bentsur,s ...
Cached Biology Technology:Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules 2Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2
(Date:9/30/2014)... WASHINGTON, D.C., September 30, 2014--Sea monkeys have captured the ... of their easily observable life cycle -- sold as ... and mate given little more than a tank of ... a shorter-term pattern: Like other zooplankton, brine shrimp vertically ... conditions, coming closer to the surface at night and ...
(Date:9/30/2014)... LA JOLLAJoseph Ecker, a Salk professor and Howard ... staff scientist, have been named recipients in the ... of Health (NIH) through the BRAIN (Brain Research ... in neuroscience. The grant, announced September 30, provides ... Salk scientists over three years. , The BRAIN ...
(Date:9/30/2014)... (PCE) in drinking water may increase the risk ... new study led by a Boston University School ... in the journal Environmental Health , compared ... 1,766 women in Cape Cod, Ma., where water ... early 1980s by the installation of vinyl-lined asbestos ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Salk scientists receive $3 million for BRAIN Initiative grant 2Contaminated water linked to pregnancy complications, BU study finds 2
... due to loss of blood flow to the spine returned ... of human spinal stem cells (hSSCs), researchers from the University ... study, led by Martin Marsala, M.D., UC San Diego professor ... of the journal Neuroscience, which is now online. , “We ...
... a heart healthy diet can reduce cardiovascular disease risks ... at macadamia nuts because they are not currently included ... tree nuts are recommended as part of a healthy ... in nutritional sciences. "Macadamia nuts have higher levels of ...
... sea ice is melting at a significantly faster rate ... a new study concludes. The research, by scientists at ... University of Colorado's National Snow and Ice Data Center ... more rapidly than estimated by any of the 18 ...
Cached Biology News:Human stem cell treatment restores motor function in paralyzed rats 2Human stem cell treatment restores motor function in paralyzed rats 3Hawaiian treasure, macadamia nuts good for the heart 2Arctic ice retreating more quickly than computer models project 2Arctic ice retreating more quickly than computer models project 3
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
CHIMAERIC HUMAN IgA2 ANTI NP...
... Zero Background/Kan Cloning Kit includes ... resistance for selection in E. ... positive selection to eliminate high ... of the reagents you need ...
Biology Products: